StreetAlpha.app
Home › Stocks › RGEN

Repligen Corp (RGEN)

Healthcare
$162.18
▼ −0.37%
LAST CLOSE · NOV 17

Repligen makes bioprocessing equipment and consumables used to manufacture biological drugs. It last closed at $162.18 on Nov 17, down 0.37% on the day. The average 12-month price target from 4 analysts is $207.50 (+27.9% from the last close), with a high of $225.00 and a low of $180.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in RGEN, 0% of them bullish and 100% bearish. In the past 30 days there were 9 dark pool prints totaling $16.9M, the largest $3.2M.

AI Auto Pilots
Is RGEN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$805.6M
+13.8% vs a year ago
Net income
−$11.8M
−779.2% vs a year ago
EPS (diluted)
−$0.21
−1150.0% vs a year ago
Free cash flow
$106.7M
13.2% margin
Valuation
Market cap
$10.4B
63.9M shares
P/E
–
No P/E while losing money
Price to sales
12.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$727.0M
At Sep 30
Debt
$555.6M
At Sep 30
Shareholder equity
$2.1B
Shares outstanding
63.9M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $670.5M$670.5MFY2021FY2022: $801.5M$801.5MFY2022FY2023: $632.4M$632.4MFY2023FY2024: $634.4M$634.4MFY2024FY2025: $738.3M$738.3MFY2025

From RGEN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
3 Buy1 Hold0 Sell
Each firm's latest rating on RGEN in the past 90 days
Average 12-month target
$207.50
▲ 27.9% upside

Based on 4 analysts who set a price target on RGEN in the past 90 days. The average target is $207.50, with a high of $225.00 and a low of $180.00, compared with the last close of $162.18.

Low $180.00Avg $207.50High $225.00
Blue marker: last close $162.18
Highest target$225.00
Average target$207.50
Lowest target$180.00
Latest rating changes
RBC CapitalTarget raised
Oct 28Buy$160 → $200
Canaccord GenuityMaintained
Oct 19Hold$180
BarclaysMaintained
Oct 7Buy$225
UBSMaintained
Sep 9Buy$225
Wells FargoMaintained
Jul 30Buy$185
DateFirmActionRatingPrice target
Oct 28RBC CapitalTarget raisedBuy$160 → $200
Oct 19Canaccord GenuityMaintainedHold$180
Oct 7BarclaysMaintainedBuy$225
Sep 9UBSMaintainedBuy$225
Jul 30Wells FargoMaintainedBuy$185
Loading…

Technical Analysis

RGEN · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 8% below its 20 day and 9% below its 50 day average. It is 10% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 40). The nearest support is the swing low (Sep 10) at $161.14, and the nearest resistance the Pivot at $162.45.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 4.7%/day
Key levels
$198.8752 week high+22.6%
$184.28Swing high (Nov 4)+13.6%
$176.9250 day average+9.1%
$174.9020 day average+7.8%
$166.49100 day average+2.7%
$164.64Pivot R1+1.5%
$162.45Pivot+0.2%
$162.18Last close
$161.14Swing low (Sep 10)−0.6%
$160.00Pivot S1−1.3%
$145.39200 day average−10.4%
$100.9952 week low−37.7%
Indicators
RSI (14)39.65Weak, oversold below 30Neutral
MACD-3.29Below its signal lineBearish
Stochastic6.9Near the bottom of its rangeOversold
ADX (14)13.7No clear trend
Williams %R-93.8Oversold below −80, overbought above −20Oversold
CCI (20)-173.3Oversold below −100, overbought above 100Oversold
Rate of change−9.0%Change over 10 sessionsBearish
ATR (14)$7.68Typical daily range, 4.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for RGEN

What happened before

See how RGEN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RGEN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RGEN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Sep 21 – Sep 21
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
9
Notional
$16.9M
Largest print
$3.2M
Loading…

RGEN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲305 buying vs 192 selling
  • ▲Held by funds +7.5 pts
  • ▲Funds holding +43
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding535492+8.7%
In funds' top 10115+120.0%
Held by funds127.7%120.2%+7.5 pts
New / increased106 / 19993 / 179+12.1%
Reduced / sold out135 / 57143 / 59−5.0%
Put/call ratio8.617.77+10.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RGEN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RGEN is in one of them and how their past RGEN trades turned out.

RGEN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RGEN in an article yet. Here's the latest on the wider market.

RGEN Congress Trades

All congress trades →
Trades, 12 months
4
Buys
1
25%
Sells
3
75%
People
2
Last filed Jul 1
Who traded RGEN · since 2022
Latest 5 filings of 12
$1K – $15KTraded May 22, 2026Filed Jul 1, 2026
$1K – $15KTraded Oct 31, 2025Filed Nov 21, 2025
$1K – $15KTraded Oct 30, 2025Filed Nov 21, 2025
$1K – $15KTraded Oct 30, 2025Filed Nov 21, 2025
$1K – $15KTraded Jul 22, 2025Filed Aug 13, 2025
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$1K – $15KMay 22, 2026Jul 1, 202640 d
Lisa McClainR · MISell$1K – $15KOct 31, 2025Nov 21, 202521 d
Lisa McClainR · MISell$1K – $15KOct 30, 2025Nov 21, 202522 d
Lisa McClainR · MIBuy$1K – $15KOct 30, 2025Nov 21, 202522 d
Lisa McClainR · MIBuy$1K – $15KJul 22, 2025Aug 13, 202522 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Repligen

Repligen is a life sciences company based in Waltham, Massachusetts, that makes equipment and consumables used to manufacture biological drugs. Its product lines cover filtration, chromatography, process analytics and proteins, including filters, tangential flow systems, columns that come already packed with resin, and fluid management parts. Its main customers are drug developers, contract manufacturers and other life science companies that make antibody-based drugs, vaccines, and cell and gene therapies.

Headquarters
Waltham, MA